<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: In vitro and in vivo studies have demonstrated neuroprotective actions of <z:chebi fb="32" ids="30145">lithium</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>The present study investigated the effect of a low dose of <z:chebi fb="32" ids="30145">lithium</z:chebi> on <z:mpath ids='MPATH_124'>infarct</z:mpath> volume and neurological outcome as well as on apoptotic and inflammatory processes in rats exposed to focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: <z:hpo ids='HP_0002637'>Cerebral ischemia</z:hpo> was induced by middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) for 90 minutes followed by reperfusion </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="32" ids="30145">Lithium</z:chebi> (1 mmol/kg) was given subcutaneously daily for 14 days before the <z:hpo ids='HP_0003674'>onset</z:hpo> of MCAO and 2 days thereafter </plain></SENT>
<SENT sid="4" pm="."><plain>Blood parameters and cerebral blood flow were assessed before, during, and after MCAO </plain></SENT>
<SENT sid="5" pm="."><plain>Rats were examined for neurological deficits 24 and 48 hours after MCAO </plain></SENT>
<SENT sid="6" pm="."><plain>Two days after MCAO, the brains were removed for immunohistochemical evaluation of caspase-3, terminal deoxynucleotidyl transferase-mediated <z:chebi fb="0" ids="17625">dUTP</z:chebi> nick end labeling (TUNEL), activated microglia, and the expression of AP-1 proteins (c-Fos and c-Jun) </plain></SENT>
<SENT sid="7" pm="."><plain><z:mpath ids='MPATH_124'>Infarct</z:mpath> volume was assessed by <z:chebi fb="0" ids="52815">cresyl violet</z:chebi> staining </plain></SENT>
<SENT sid="8" pm="."><plain>RESULTS: Pretreatment with <z:chebi fb="32" ids="30145">lithium</z:chebi> did not alter cerebral blood flow or blood parameters </plain></SENT>
<SENT sid="9" pm="."><plain>Neurological deficits were significantly decreased in rats treated with <z:chebi fb="32" ids="30145">lithium</z:chebi> at 24 and 48 hours after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain><z:mpath ids='MPATH_124'>Infarct</z:mpath> volume was reduced in rats treated with <z:chebi fb="32" ids="30145">lithium</z:chebi> at 48 hours after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain><z:chebi fb="32" ids="30145">Lithium</z:chebi> significantly decreased the <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced caspase-3 immunoreactivity and TUNEL staining as well as the AP-1 protein expression in the penumbra of the ischemic cortex </plain></SENT>
<SENT sid="12" pm="."><plain>No changes in activated microglia were observed </plain></SENT>
<SENT sid="13" pm="."><plain>CONCLUSIONS: The present study demonstrates that <z:hpo ids='HP_0011010'>chronic</z:hpo> treatment with <z:chebi fb="32" ids="30145">lithium</z:chebi> at a low dose exhibits neuroprotection in transient focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="14" pm="."><plain>Antiapoptotic mechanisms are involved in the <z:chebi fb="32" ids="30145">lithium</z:chebi>-induced neuroprotective effects </plain></SENT>
</text></document>